MedPath
HSA Product

SYNERRV CELECOXIB HARD CAPSULES 100MG

Product approved by Health Sciences Authority (SG)

Basic Information

SYNERRV CELECOXIB HARD CAPSULES 100MG

CAPSULE

Regulatory Information

SIN16253P

June 29, 2021

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XM01AH01

Company Information

SYNERRV (S) PTE. LTD.

SYNERRV (S) PTE. LTD.

Active Ingredients

CELECOXIB

Strength: 100.00MG

Detailed Information

Contraindications

**CONTRAINDICATION:** Celecoxib is contraindicated in: - Patients with known hypersensitivity to celecoxib or any other ingredient of the product (see List of excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Patients with known sulfonamide hypersensitivity. - Patients with active peptic ulceration or gastrointestinal (GI) bleeding. - Patients who have experienced asthma, urticaria or allergic-type reactions after taking acetylsalicylic acid (ASA \[aspirin\]) or other non-steroidal anti-inflammatory drugs (NSAIDs), including other cyclooxygenase-2 (COX-2) specific inhibitors. - Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see Special warnings and precautions for use). - Congestive heart failure (NYHA II–IV). - Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

Indication Information

**INDICATION:** - Symptomatic treatment of osteoarthritis (OA) and rheumatoid arthritis (RA). - Management of acute pain in adults. - Treatment of primary dysmenorrhoea. - Relief of signs and symptoms of ankylosing spondylitis (AS). - Management of chronic low back pain. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks, taking into consideration other available therapeutic options.

© Copyright 2025. All Rights Reserved by MedPath